Cancer Treatment

American Shared Hospital Services Announces Official Notice of Certificate of Need Approval to Acquire the Technology to Construct and Operate a Proton Beam Radiation Therapy Facility in the State of Rhode Island

Dec 17, 2024

SAN FRANCISCO, Dec. 17, 2024 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the “Company” or “AMS”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced that its wholly owned subsidiary, ASHS – Rhode Island Proton Beam Radiation Therapy, LLC, has officially obtained a Certificate of Need (CON) to acquire the technology necessary to construct and...

American Shared Hospital Services Reports Third Quarter 2024 Financial Results

Nov 13, 2024

- Revenue increases 36.3% period over period - Conference Call on November 13th at 1:00 pm ET SAN FRANCISCO, CA, November 13, 2024 ‒ American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Highlights Total revenue in...

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Nov 1, 2024

PITTSBURGH, PA, November 1, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of...

Immunophotonics to Present at the 2024 ThinkEquity Conference

Oct 28, 2024

St. Louis, Missouri, October 28, 2024 - PRISM MediaWire - Immunophotonics, Inc. a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial...

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

Sep 24, 2024

PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with...

American Shared Hospital Services Announces Second Quarter 2024 Earnings Conference Call

Aug 14, 2024

Call Scheduled for Today at 6:30 PM ET SAN FRANCISCO, August 14, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its second quarter 2024 financial results today, August 14th at 6:30 pm ET / 3:30 pm PT. The second quarter 2024 financial results press release...

NEWSROOM

American Shared Hospital Services Announces Official Notice of Certificate of Need Approval to Acquire the Technology to Construct and Operate a Proton Beam Radiation Therapy Facility in the State of Rhode Island

American Shared Hospital Services Reports Third Quarter 2024 Financial Results

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Immunophotonics to Present at the 2024 ThinkEquity Conference

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

American Shared Hospital Services Announces Second Quarter 2024 Earnings Conference Call

Contact Us